Joshua Stern, DVM, PhD, of North Carolina State University, has been studying a formulation of the medication rapamycin (sirolimus) that has been shown to forestall progressive ventricular thickening over a six-month period in cats with hypertrophic cardiomyopathy (HCM). Based in part upon these initial findings, the FDA recently granted conditional approval for the use of this drug in cats with HCM, and subjects are currently being enrolled for a follow-up 12-month clinical trial (the HALT HCM study).
To continue reading this article or issue you must be a paid subscriber. Sign in
Subscribe to CatWatch
Get the next year of CatWatch for just $20. And access all of our back issues and online content free of charge.
Subscribe today and save 50% off the regular rate!
